

扶正祛痰方联合顺铂对 LL/2 荷瘤小鼠非小细胞肺癌血清 IL-2 水平的影响^{*}

赵艳莉 吴召利 李仁廷

(陕西中医药大学附属医院肿瘤一科, 陕西 咸阳 712000)

摘要:目的 观察扶正祛痰方、顺铂及扶正祛痰方与顺铂联合治疗非小细胞肺癌的疗效,探索扶正祛痰方的抗癌机制及对顺铂的增效减毒作用。方法 将40只小鼠分为对照组、扶正祛痰方组、顺铂组和联合组,每组各10只小鼠。对照组给予常规喂养,扶正祛痰方组每天中药灌胃,顺铂组腹腔注射顺铂,每周两次,联合组结合上述两种方法给药,所有小鼠21天后处死。小鼠处死前取血,采用ELISA法检测IL-2;小鼠处死后,测肿瘤体积及脾脏、胸腺重量。结果 扶正祛痰方组、顺铂组和联合组中的抑瘤率分别为66.9%、68.8%和71.8%;扶正祛痰方组和联合组肺癌小鼠的脾脏指数和胸腺指数较顺铂组高,且差异具有统计学意义($P < 0.05$);扶正祛痰方组和联合组小鼠血清中IL-2也较顺铂组高,差异具有统计学意义($P < 0.05$)。结论 扶正祛痰方具有一定的抑瘤作用,且扶正祛痰方联合顺铂同时使用,疗效更加确定,并能有效减少顺铂的毒副作用。

关键词:扶正祛痰方;顺铂;非小细胞肺癌

中图分类号:R734.2 文献标识码:A 文章编号:2096-1340(2017)04-0101-04

DOI:10.13424/j.cnki.jsctcm.2017.04.033

The Effect of the Health-enhancing and Phlegm-removing Prescription Combined with Cisplatin on IL-2 Levels in NSCLC Serum of Mice Bearing LL/2 Neoplasm

Zhao Yanli Wu zhaoli Li Renting

(Oncology Department, the First Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang 712000, China)

Abstract Objective: To observe the effect of Health-enhancing and Phlegm-removing Prescription, cisplatin as well as both combination on non-small cell lung cancer (NSCLC) and to explore the anti-cancer mechanism of Health-enhancing and Phlegm-removing Prescription as well as the cisplatin's action in enhancing the therapeutic effects and reducing poisonousness. **Method:** Totally 40 mice were evenly divided into the control, HPP (Health-enhancing and Phlegm-removing Prescription), CS (cisplatin) and combining group. The control group received conventional feeding, HPP group Chinese medicine lavage every day, CS group intraperitoneally injection of cisplatin for twice a week and the combining group was in combination of the above two methods, all mice put to death after 21 days. The mice were taken blood before executed to determine IL-2 levels by ELISA method. After the mice were executed, the tumor volume and the spleen as well as thymus weight were measured. **Results:** The tumor inhibiting rates of the HPP, CS and combining group were 66.9%, 68.8% and 71.8% respectively. The splenic and thymus indexes of the lung cancer mice in the HPP and combining group were higher than the CS group, and the difference was statistically significant ($P < 0.05$). The serum IL-2 levels of in the HPP and combining group were also higher than the CS group, and the difference was statistically significant ($P < 0.05$). **Conclusion:** The Health-enhancing and Phlegm-removing Prescription has certain tumor suppression effect and its combination with cisplatin is better for it can effectively reduce the

* 基金项目:咸阳市科技局项目(2012K16-02);陕西中医药大学附属医院科研项目(2014-30)